← BioCardia, Inc. (BCDA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
BioCardia, Inc. (BCDA)
Biological Products, (No Diagnostic Substances) · market cap $16M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
1
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
BioCardia, Inc. (BCDA) is a micro-cap clinical-stage biotech (~$11M market cap, ~$0.83/share) developing an autologous cell therapy in Phase 3 for systolic heart failure. The company has no disclosed near-term catalysts on the calendar and limited publicly available financial detail, creating a high-uncertainty, low-liquidity profile.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Autologous cell therapy | Phase 3 | Heart Failure, Systolic |
Price & technical context
3-month
-12.5%
6-month
-11.0%
12-month
-29.1%
52-wk range
$0.77–$1.56
vs 50-day MA
+4.3%
vs 200-day MA
-6.2%
Realized vol
68.1%
Max drawdown
-75.5%
Daily closes through 2026-09-25. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BCDA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.